Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists
A technology for thrombin receptor, platelet aggregation, used in the field of diagnostic assays
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0068] Using VERIFYNOW™ IIb / IIIa Assay (Accumetrics, Inc., San Diego, Calif.) and using PAR-1 Thrombin Receptor Activating Peptide (TRAP-1) as a platelet activator, experiments were performed to determine the PAR-1 antagonist E5555 ( Eisai Ltd.) dose-dependent inhibition of platelets.
[0069] Dose response tests were performed using 3.7 [mu]M TRAP-1. E5555 was used at final concentrations of 30 ng / ml, 10 ng / ml, 5.0 ng / ml and 1.0 ng / ml. 20 [mu]L of each stock solution was added to 2.0 ml of whole blood (1:100 dilution) and mixed carefully to avoid hemolysis. After mixing, blood samples were incubated at 37°C for 30 minutes prior to the platelet inhibition assay.
[0070] Blood samples from four human donors were run in duplicate at baseline and each of the four E5555 concentrations. As expected, the level of platelet inhibition measured at a given E5555 concentration varied from donor to donor. Actual results for the four donors were on average slightly lower than expected...
PUM
Property | Measurement | Unit |
---|---|---|
diameter | aaaaa | aaaaa |
volume | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com